Literature DB >> 23229717

Bayesian indirect and mixed treatment comparisons across longitudinal time points.

Ying Ding1, Haoda Fu.   

Abstract

Meta-analysis has become an acceptable and powerful tool for pooling quantitative results from multiple studies addressing the same question. It estimates the effect difference between two treatments when they have been compared head-to-head. However, limitations occur when there are more than two treatments of interest, and some of them have not been compared in the same study. Indirect and mixed treatment modeling extends meta-analysis methods to enable data from different treatments and trials to be synthesized, without requiring head-to-head comparisons among all treatments; thus, allowing different treatments to be compared. Traditional indirect and mixed treatment comparison methods consider a single endpoint for each trial. We extend the current methods and propose a Bayesian indirect and mixed treatment comparison longitudinal model that incorporates multiple time points and allows indirect comparisons of treatment effects across different longitudinal studies. The proposed model only uses summary level longitudinal data. This model is particularly useful when a meta-analysis is performed on studies with different durations. It enables the borrowing of information from shorter studies even in the situation where the primary interest is in a time point beyond the duration of some of these shorter studies. We performed simulation studies, which demonstrate that the proposed method performs well and yields better estimations compared with other single time point meta-analysis methods. We apply our method to a set of studies from patients with type 2 diabetes.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23229717     DOI: 10.1002/sim.5688

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  8 in total

1.  Detecting outlying trials in network meta-analysis.

Authors:  Jing Zhang; Haoda Fu; Bradley P Carlin
Journal:  Stat Med       Date:  2015-04-08       Impact factor: 2.373

2.  Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom.

Authors:  Lindsay Claxton; Robert Hodgson; Matthew Taylor; Bill Malcolm; Ruth Pulikottil Jacob
Journal:  Pharmacoeconomics       Date:  2017-02       Impact factor: 4.981

3.  Classifying information-sharing methods.

Authors:  Georgios F Nikolaidis; Beth Woods; Stephen Palmer; Marta O Soares
Journal:  BMC Med Res Methodol       Date:  2021-05-22       Impact factor: 4.615

Review 4.  The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis.

Authors:  Andriy Danyliv; Julie Glanville; Rachael McCool; Alberto Ferreira; Adrian Skelly; Ruth Pulikottil Jacob
Journal:  Adv Ther       Date:  2017-02-10       Impact factor: 3.845

5.  Modelling time-course relationships with multiple treatments: Model-based network meta-analysis for continuous summary outcomes.

Authors:  Hugo Pedder; Sofia Dias; Margherita Bennetts; Martin Boucher; Nicky J Welton
Journal:  Res Synth Methods       Date:  2019-05-29       Impact factor: 5.273

Review 6.  Uptake of methodological advances for synthesis of continuous and time-to-event outcomes would maximize use of the evidence base.

Authors:  Suzanne C Freeman; Alex J Sutton; Nicola J Cooper
Journal:  J Clin Epidemiol       Date:  2020-05-12       Impact factor: 6.437

7.  Bayesian splines versus fractional polynomials in network meta-analysis.

Authors:  Andreas Heinecke; Marta Tallarita; Maria De Iorio
Journal:  BMC Med Res Methodol       Date:  2020-10-20       Impact factor: 4.615

8.  Challenges of modelling approaches for network meta-analysis of time-to-event outcomes in the presence of non-proportional hazards to aid decision making: Application to a melanoma network.

Authors:  Suzanne C Freeman; Nicola J Cooper; Alex J Sutton; Michael J Crowther; James R Carpenter; Neil Hawkins
Journal:  Stat Methods Med Res       Date:  2022-01-19       Impact factor: 2.494

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.